Pooled analyses of eribulin in metastatic breast cancer patients with at least one prior chemotherapy.
Fiche publication
Date publication
août 2016
Journal
Annals of oncology : official journal of the European Society for Medical Oncology
Auteurs
Membres identifiés du Cancéropôle Est :
Pr PIVOT Xavier
Tous les auteurs :
Pivot X, Marmé F, Koenigsberg R, Guo M, Berrak E, Wolfer A
Lien Pubmed
Résumé
Based on data from two multicenter, phase III clinical trials (Studies 301 and 305), eribulin (a microtubule dynamics inhibitor) is indicated in the European Union (EU) for patients with locally advanced or metastatic breast cancer (MBC) after ≥1 prior chemotherapy for advanced disease, including an anthracycline and a taxane in either the adjuvant or metastatic setting. Data from Studies 305 and 301 were pooled to investigate the efficacy of eribulin in various subgroups of patients who matched the EU label, including those with human epidermal growth factor receptor 2 (HER2)-negative and triple-negative disease.
Mots clés
clinical trial, eribulin, metastatic breast cancer, pooled analysis, survival, triple-negative breast cancer
Référence
Ann. Oncol.. 2016 Aug;27(8):1525-31